Brabant G, Jüppner H, Kirschner M, Böker K, Schmidt F W, Hesch R D
Klin Wochenschr. 1986;64 Suppl 6:108-11.
The acute effects of human atrial natriuretic peptide (ANP) were investigated in 10 patients with liver cirrhosis and ascites. In all patients, diuresis and natriuresis were stimulated with a wide individual variation (50 to 500%) in response to a bolus injection of 30 micrograms ANP. No side effects of treatment were observed. Continuous infusion of ANP (300 micrograms/10 h/d) in a patient with liver cirrhosis and ascites, resistant to conservative forms of diuretic therapy, resulted in an initial increase of diuresis and natriuresis which subsequently returned to pretreatment levels. After initiation of pulsatile nocturnal treatment (5 pulses of 30 micrograms ANP every 3 h), diuresis increased, leading to a persistent normalization of sodium and chloride excretion. The patient lost 8 kg of weight during 16 days of treatment. Out of 3 additional patients on the same therapeutic regime, only one experienced a weight loss of 5 kg due to increased natriuresis and chloruresis. The remaining 2 patients did not respond during 5 resp. 7 days of therapy.
对10例肝硬化腹水患者研究了人心房利钠肽（ANP）的急性效应。所有患者在静脉推注30微克ANP后，均出现利尿和利钠作用，个体差异较大（50%至500%）。未观察到治疗的副作用。对一名肝硬化腹水患者持续输注ANP（300微克/10小时/天），该患者对传统利尿治疗无效，输注后最初出现利尿和利钠增加，但随后又恢复到治疗前水平。开始夜间脉冲式治疗（每3小时注射5次30微克ANP）后，尿量增加，钠和氯排泄持续正常化。该患者在16天的治疗期间体重减轻了8千克。另外3例采用相同治疗方案的患者中，只有1例因利钠和利氯作用增强而体重减轻了5千克。其余2例患者在5天和7天的治疗期间无反应。
